AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive ...
AstraZeneca's NIAGARA Phase III trial showed IMFINZI (durvalumab) plus chemotherapy improved event-free survival (EFS) and overall survival (OS) over neoadjuvant chemotherapy alone. The IMFINZI regimen reduced disease progression risk by 32% and death risk by 25%.
Reference News
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive ...
AstraZeneca's NIAGARA Phase III trial showed IMFINZI (durvalumab) plus chemotherapy improved event-free survival (EFS) and overall survival (OS) over neoadjuvant chemotherapy alone. The IMFINZI regimen reduced disease progression risk by 32% and death risk by 25%.